|
Automated Multiple Needle Detection For Brachytherapy
Application
Workflow to detect multiple needles in three-dimensional ultrasound images.
Key Benefits
Does not require specialized ultrasound pulses or hardware.
Detects multiple needles with low error.
Market Summary
Many minimally invasive procedures require inserting a needle to access a target site inside the patient body, avoiding the requirement...
Published: 11/2/2020
Contributor(s): Yupei Zhang, Pretesh Patel
|
|
Amino Acid-Derived Radiotracer Compounds for PET Cancer Imaging
Application
New class of fluorine-18 labeled amino acid-derived radiotracer compounds for positron emission tomography (PET) cancer imaging.
Key Benefits
Next generation of cancer imaging agents.
Enhanced sensitivity to detect glioblastoma, prostate cancer and other cancers.
Market Summary
PET imaging is a type of nuclear medicine procedure...
Published: 11/2/2020
Contributor(s): Mark Goodman, Lanny Liebeskind, Thomas Pickel
|
|
Photocaged Cytokines for Cancer Immunotherapy
Application
Light-responsive cytokine prodrugs with controlled activation for improved cancer immunotherapy.
Key Benefits
Prolonged circulation and biased immune cell-selectivity.
Controlled local activation, reduces off-target toxicity.
Requires less frequent dosing.
Market Summary
While recombinant cytokines hold great potential for cancer...
Published: 11/2/2020
Contributor(s): Priscilla Do
|
|
PNP-based Solid Tumor Therapy in Conjunction with Checkpoint Blockade Inhibitors
Application
Treatment of solid tumors combining purine nucleoside phosphorylase (PNP) technology with checkpoint blockade inhibition.
Key Benefits
Safe and effective method for markedly enhancing checkpoint blockade therapy for refractory tumors.
Checkpoint inhibitor therapy is FDA-approved and already in use.
Market Summary
Checkpoint blockade...
Published: 10/22/2020
Contributor(s): Turang Behbahani, Regina Rab, Annette Ehrhardt, Jeong Hong, Disha Joshi
|
|
Galectin-9 Directed CAR T-cells for Overcoming Resistance to Chemotherapy in Hematological Malignancies
Application
Anti-human Galectin-9-directed chimeric antigen receptor (CAR) T-cells for treatment of hematological malignancies (B-ALL, T-ALL, and DLBCL) in normal, overweight, and obese patients.
Key Benefits
Can be used as a stand-alone or in-combination product to treat patients with hematological malignancies, particularly overweight and obese...
Published: 10/13/2020
Contributor(s): Curtis Henry, Miyoung (Mi-Young) Lee, Sunil Raikar, Jamie Hamilton, Anthony Ross
|
|
Class of Bcl-2 Inhibitors as Anti-Cancer Therapeutics
Application
Small molecule inhibitors of Bcl-2, an anti-apoptotic protein, for cancer treatment.
Key Benefits
Developed specifically to target the BH4 homology domain of Bcl-2 in order to improve binding affinity and anti-tumor efficacy over other Bcl-2 inhibitors.
Compounds may simultaneously suppress a wider range of anti-apoptotic proteins than...
Published: 10/2/2020
Contributor(s): Xingming Deng, Jia Zhou, Chunyong Ding
|
|
Development of Bax Activators as a New Class of Anti-Cancer Drugs
Application
Therapeutic for treatment of cancer.
Key Benefits
The first in class, potent and selective agonists of Bax with nanomolar activity.
Bax activators have significantly less apoptotic effect on normal cells as compared to cancer cells.
Compounds have shown high selectivity for tumor cells.
Technical Summary
Patients with cancer have...
Published: 10/2/2020
Contributor(s): Xingming Deng, Jia Zhou, Chunyong Ding
|
|
Drug Combination to Treat Lung Cancer Metastasis
Application
Combination product co-targeting PDH and GLUT1 to inhibit lung cancer metastasis.
Key Benefits
Combination of drugs exhibits greater synergism in cancer cell lines (H1299, 4T1, H1792).
Has potential to prevent metastasis in a variety of cancers.
Decreases both cell viability and invasive area.
Repurposed drugs.
Market Summary
Lung...
Published: 10/1/2020
Contributor(s): Malathy (mala) Shanmugam, Adam Marcus
|
|
Small Molecule for Treatment of Alzheimer’s Disease and Cancer
Application
New family of AEP inhibitors for neurodegenerative diseases or cancer.
Key Benefits
Non peptide, small molecule inhibitor of AEP.
Alzheimer candidate is Blood-Brain Barrier (BBB) permeable.
AEP inhibitors are a potential candidate for AD and cancer.
Market Summary
Alzheimer’s disease (AD) is the most common dementia affecting...
Published: 10/1/2020
Contributor(s): Keqiang Ye
|
|
Small Molecule for Treatment of Aggressive Prostate Cancer
Application
Small molecule drug combination to treat castration-resistant prostate cancer.
Key Benefit
Restores response to antigen deprivation therapy in castration-resistant prostate cancer.
Market Summary
Besides skin cancer, prostate cancer is the most common cancer in American men (American Cancer Society). Prostate cancer is also the second...
Published: 10/1/2020
Contributor(s): Carlos Moreno
|
Emory UniversityOffice of Technology Transfer